Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kalaris Therapeutics (KLRS) Liabilities and Shareholders Equity (2019 - 2020)

Kalaris Therapeutics (KLRS) has 2 years of Liabilities and Shareholders Equity data on record, last reported at $393.7 million in Q3 2020.

  • For Q3 2020, Liabilities and Shareholders Equity changed N/A year-over-year to $393.7 million; the TTM value through Dec 2020 reached $511.6 million, changed N/A, while the annual FY2019 figure was $139.4 million, N/A changed from the prior year.
  • Liabilities and Shareholders Equity reached $393.7 million in Q3 2020 per KLRS's latest filing, up from $117.8 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $393.7 million in Q3 2020 and bottomed at $117.8 million in Q2 2020.